Demoralization

EQS-News: Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer

Retrieved on: 
Sunday, January 22, 2023
Psilocybin, Cancer, Mood disorder, Mental health, Anxiety, Commercial, Biotechnology, Innes, Learned helplessness, Research, Addiction medicine, Depression, Orexo, Series, CNS, Growth, Patient, Novartis, Psychotherapy, Demoralization, Grammatical mood, Chairperson, Senior, Pharmaceutical industry

New York, NY, January 5, 2023 - Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.

Key Points: 
  • New York, NY, January 5, 2023 - Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.
  • Innes Meldrum has nearly 30 years of global experience in the biotechnology and technology industries, having most recently served as Senior Vice President and Chief Commercial Officer for Otsuka Pharmaceuticals North America.
  • “We are delighted to have Innes join Reset Pharma as CEO,” said Philip Taub, Chair of the Board.
  • I warmly welcome Innes and look forward to working with him and the entire Reset Pharma team.

Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer

Retrieved on: 
Thursday, January 5, 2023
Psilocybin, Cancer, Mood disorder, Mental health, Anxiety, Commercial, Biotechnology, Innes, Learned helplessness, Research, Addiction medicine, Depression, Orexo, Series, CNS, Growth, Patient, Novartis, Psychotherapy, Demoralization, Grammatical mood, Chairperson, Senior, Pharmaceutical industry

NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.

Key Points: 
  • NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.
  • Innes Meldrum has nearly 30 years of global experience in the biotechnology and technology industries, having most recently served as Senior Vice President and Chief Commercial Officer for Otsuka Pharmaceuticals North America.
  • “We are delighted to have Innes join Reset Pharma as CEO,” said Philip Taub, Chair of the Board.
  • I warmly welcome Innes and look forward to working with him and the entire Reset Pharma team.

EQS-News: Reset Pharmaceuticals announces appointment of neuroscience industry leader Lisa Deschamps to the Board of Directors

Retrieved on: 
Thursday, November 3, 2022
Depression, MBA, Frontotemporal dementia, Cancer, CNS, Board, Learned helplessness, Risk, ALS, Anxiety, Novartis Gene Therapies, Central Waqf Council, Novartis, Psilocybin, Strategic planning, Patient, Neurodegeneration, Mood disorder, FTD, Psychiatry, Grammatical mood, Forward-looking statement, Amyotrophic lateral sclerosis, Mental health, Demoralization, Suicide, Coronavirus Scientific Advisory Board (Turkey), Pharmaceutical industry, Neuroscience

Ms. Deschamps is a highly experienced pharmaceutical executive who has worked at Board and senior management levels with global responsibilities.

Key Points: 
  • Ms. Deschamps is a highly experienced pharmaceutical executive who has worked at Board and senior management levels with global responsibilities.
  • Before this, she was Worldwide Business Head, Neuroscience at Novartis, where she was responsible for the development and commercialization of the neuroscience portfolio.
  • She has been involved in more than a dozen successful product approvals and launches in many therapeutic areas, including in neuroscience.
  • We are very happy to welcome Lisa to the Board, said Philip Taub, Chair of the Board of Reset Pharma.

Reset Pharmaceuticals announces appointment of neuroscience industry leader Lisa Deschamps to the Board of Directors

Retrieved on: 
Wednesday, November 2, 2022
Depression, MBA, Frontotemporal dementia, Cancer, CNS, Board, Learned helplessness, GLOBE, Risk, ALS, Anxiety, Central Waqf Council, Novartis Gene Therapies, Novartis, Psilocybin, Strategic planning, Patient, Neurodegeneration, Mood disorder, FTD, Psychiatry, Grammatical mood, Forward-looking statement, Amyotrophic lateral sclerosis, Mental health, Demoralization, Suicide, Coronavirus Scientific Advisory Board (Turkey), Pharmaceutical industry, Neuroscience

Ms. Deschamps is a highly experienced pharmaceutical executive who has worked at Board and senior management levels with global responsibilities.

Key Points: 
  • Ms. Deschamps is a highly experienced pharmaceutical executive who has worked at Board and senior management levels with global responsibilities.
  • Before this, she was Worldwide Business Head, Neuroscience at Novartis, where she was responsible for the development and commercialization of the neuroscience portfolio.
  • She has been involved in more than a dozen successful product approvals and launches in many therapeutic areas, including in neuroscience.
  • We are very happy to welcome Lisa to the Board, said Philip Taub, Chair of the Board of Reset Pharma.

Torque3's Deeply Immersive Task-Oriented Therapy Plus (TOT+) Offers A Revolutionary Platform for Stroke and TBI Rehabilitation

Retrieved on: 
Wednesday, June 1, 2022
Stroke, Research, Program, Perception, Salt Lake, Environment, Summer, Therapy, Machine learning, Brain, Robotics, Job, Demoralization, Risk, Movement, Rehabilitation, Collection, Survivor, Virtual reality, TBI, Pharmaceutical industry, Aquaculture, TOT

CENTERVILLE, Utah, June 1, 2022 /PRNewswire-PRWeb/ -- Torque3, the company developing a rehabilitation solution for stroke and TBI survivors, announced today that the principal therapeutic factor in its intense, deeply immersive neurorehabilitation platform is Task‐Oriented Therapy Plus, or TOT+ (patent pending).

Key Points: 
  • One of the most common approaches to restoring function after a stroke or TBI is called Task-Oriented Training (or Task-Oriented Therapy), or "TOT" for short.
  • The Torque3 platform utilizes a collection of technologies, all to deliver the best task-oriented therapy possible.
  • These technologies include deeply immersive and responsive virtual simulations and advanced robotics, both with integrated and synchronized machine learning.
  • Right now, stroke and TBI survivors have the rare opportunity to experience this revolutionary neurorehabilitation platform.

The Law Firm of Tamara N. Holder, LLC: Female iHeart Radio/TTWN Executive Producer Alleges Years of Bullying, Ignored Complaints; 17-year Veteran Files 55-page EEOC Charge

Retrieved on: 
Monday, April 25, 2022
Professional Services, Entertainment, Communications, TV and Radio, Legal, Other Communications, Diffusion, Woman, LLC, Workplace, IHeartRadio, Equal opportunity, Sexual harassment, Radio, Fox News, Demoralization, Equal Employment Opportunity Commission, Female, Diffuse intrinsic pontine glioma, Male, Traffic message channel, Bullying, Weather

The Law Firm of Tamara N. Holder, LLC has filed a charge of discrimination with the Equal Employment Opportunity Commission, on behalf of a female, 17-year veteran employee Executive Producer for iHeart Radio and Total Traffic and Weather Network (TTWN).

Key Points: 
  • The Law Firm of Tamara N. Holder, LLC has filed a charge of discrimination with the Equal Employment Opportunity Commission, on behalf of a female, 17-year veteran employee Executive Producer for iHeart Radio and Total Traffic and Weather Network (TTWN).
  • She further alleges that, Despite publicly holding themselves out as maintaining a workplace that treats women with respect and dignity, iHeart/TTWN maintain a systemic structure of abuse, demoralization and psychological torture.
  • Her supervisor was previously accused, in a lawsuit by a former female reporter, of ignoring her complaints of sexual harassment by a male coworker.
  • And yet, the female employee has never been written-up or placed on a Performance Improvement Plan (PIP).

Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Related Distress

Retrieved on: 
Thursday, February 17, 2022
NASDAQ, Cumming School of Medicine, Psychotherapy, Collection, Patient, Cancer, CRD, Department, Company, Prevalence, Education, Brain, SEC, Phrase, IMPACT, Forward-looking statement, U.S. Securities and Exchange Commission, University of Calgary Faculty of Law, Security (finance), DOI, Budget, University, Clinical trial, CQD, 2009–10 Calgary Flames season, Health Canada, Anxiety, Demoralization, Annual report, Intention, Calgary Flames, Institute, Mental health, Peter L. Berger, Distress, Disorder, Grammatical mood, Mood disorder, PTSD, Marketing, Hotchkiss, Disease, The Company, Research, Coronavirus, HBI, Nature, COVID-19, Program, Pharmacotherapy, Drug development, Pharmaceutical industry, Medical device, Risk management, Medicine

Approximately 50% of cancer patients report clinical levels of psychological distress having depressed mood, anxiety, demoralization, stress-induced clinical manifestations, and reduced quality of life1.

Key Points: 
  • Approximately 50% of cancer patients report clinical levels of psychological distress having depressed mood, anxiety, demoralization, stress-induced clinical manifestations, and reduced quality of life1.
  • Up to 40% of cancer patients meet the criteria for a mood disorder requiring treatment2.
  • The EVM-101 study will directly assess the core features of CRD that are most affected and amenable to improvement following a psilocybin-based treatment.
  • Patient enrollment in the clinical trial is expected to begin late in 2022 or early in 2023.

Stephen Ross, M.D., Chair of Reset Pharma’s Scientific Advisory Board to Deliver Keynote Presentation at The End in Mind Virtual Conference

Retrieved on: 
Thursday, October 14, 2021
Cancer, Risk, Suicide, Depression, Coronavirus Scientific Advisory Board (Turkey), Grammatical mood, Policy, Psychiatry, Patient, GLOBE, Demoralization, Forward-looking statement, Learned helplessness, Psilocybin, Anxiety, Pharmaceutical industry

NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma) announced today that Stephen Ross, M.D., Chair of Reset Pharmas Scientific Advisory Board, will deliver a keynote presentation at The End in Mind virtual conference being held on October 14, 2021.

Key Points: 
  • NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma) announced today that Stephen Ross, M.D., Chair of Reset Pharmas Scientific Advisory Board, will deliver a keynote presentation at The End in Mind virtual conference being held on October 14, 2021.
  • In addition, Anthony Back, M.D., a member of Reset Pharmas Scientific Advisory Board, will participate in a panel discussion, Caring for Frontline Workers.
  • The End In Mind is a virtual conference featuring thought leaders who will discuss the future of psychedelic medicines for those facing serious illness.
  • Reset Pharma has established a highly experienced biotech development team and has a Scientific Advisory Board of leading experts in psychiatry, oncology and psychedelics.